

SUMMARY OF PRODUCT CHARACTERISTICS

BACQUIRE

(Imipenem and Cilastatin for Injection 500 mg)

1. Imipenem and Cilastatin for Injection 500 mg

Bacquire Injection 500 mg

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each vial contains

Imipenem USP (sterile)

equivalent to anhydrous Imipenem..... 500 mg

Cilastatin Sodium USP (sterile)

equivalent to anhydrous Imipenem..... 500 mg

For the full list of excipients, see **section 6.1**

3. **PHARMACEUTICAL FORM**

Powder for Injection.

4 **CLINICAL PARTICULARS¹**

4.1 **Therapeutic indications**

BACQUIRE is indicated for the treatment of the following infections in adults and children 1 year of age and above (see **sections 4.4** and **5.1**):

- complicated intra-abdominal infections
- severe pneumonia including hospital and ventilator-associated pneumonia
- intra- and post-partum infections
- complicated urinary tract infections
- complicated skin and soft-tissue infections

BACQUIRE may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 **Posology and method of administration**

Posology

The dose recommendations for **BACQUIRE** represent the quantity of imipenem/cilastatin to be administered.

The daily dose of **BACQUIRE** should be based on the type of infection and given in equally divided doses based on consideration of degree of susceptibility of the pathogen(s) and the patient's renal function (see also **sections 4.4 and 5.1**)

Adults and adolescents

For patients with normal renal function (creatinine clearance of ≥ 90 ml/min), the recommended dose regimens are:

- 500 mg/500 mg every 6 hours OR
- 1000 mg/1000 mg every 8 hours OR every 6 hours

It is recommended that infections suspected or proven to be due to less susceptible bacterial species (such as *Pseudomonas aeruginosa*) and very severe infections (e.g. in neutropenic patients with a fever) should be treated with 1000 mg/1000 mg administered every 6 hours.

A reduction in dose is necessary when creatinine clearance is < 90 ml/min (see Table below).

The maximum total daily dose should not exceed 4000 mg/4000 mg per day.

Renal impairment

To determine the reduced dose for adults with impaired renal function:

1. The total daily dose (i.e. 2000/2000, 3000/3000 or 4000/4000 mg) that would usually be applicable to patients with normal renal function should be selected.
2. From table below the appropriate reduced dose regimen is selected according to the patient's creatinine clearance. For infusion times see Method of administration.

Creatinine clearance (mL/min) is:	If TOTAL DAILY DOSE is: 2000 mg/day	If TOTAL DAILY DOSE is: 3000 mg/day	If TOTAL DAILY DOSE is: 4000 mg/day
≥ 90 (normal)	500 q6h	1000 q8h	1000 q6h
Reduced dosage (mg) for patients with renal impairment:			
$< 90 - \geq 60$	400 q6h	500 q6h	750 q8h
$< 60 - \geq 30$	300 q6h	500 q8h	500 q6h
$< 30 - \geq 15$	200 q6h	500 q12h	500 q12h

Patients with a creatinine clearance of < 15 ml/min

These patients should not receive **BACQUIRE** unless haemodialysis is instituted within 48 hours.

Patients on haemodialysis

When treating patients with creatinine clearances of <15 ml/min who are undergoing dialysis use the dose recommendation for patients with creatinine clearances of 15 to 29 ml/min (see table above).

Both imipenem and cilastatin are cleared from the circulation during haemodialysis. The patient should receive imipenem/cilastatin after haemodialysis and at 12-hour intervals timed from the end of that haemodialysis session. Dialysis patients, especially those with background central nervous system (CNS) disease, should be carefully monitored; for patients on haemodialysis, imipenem/cilastatin is recommended only when the benefit outweighs the potential risk of seizures (see **section 4.4**).

Currently there are inadequate data to recommend use of imipenem/cilastatin for patients on peritoneal dialysis.

Hepatic impairment

No dose adjustment is recommended in patients with impaired hepatic function (see **section 5.2**).

Elderly population

No dose adjustment is required for the elderly patients with normal renal function (see **section 5.2**).

Paediatric population ≥1 year of age

For paediatric patients ≥1 year of age, the recommended dose is 15/15 or 25/25 mg/kg/dose administered every 6 hours.

It is recommended that infections suspected or proven to be due to less susceptible bacterial species (such as *Pseudomonas aeruginosa*) and very severe infections (e.g. in neutropenic patients with a fever) should be treated with 25/25 mg/kg administered every 6 hours.

Paediatric population <1 year of age

Reported clinical data are insufficient to recommend dosing for children less than 1 year of age.

Paediatric population with renal impairment

Reported clinical data are insufficient to recommend dosing for paediatric patients with renal impairment (serum creatinine > 2mg/dl). See **section 4.4**.

Method of administration

BACQUIRE is to be reconstituted and further diluted (see **sections 6.2, 6.3 and 6.6**) prior to administration. Each dose of ≤ 500 mg/500 mg should be given by intravenous infusion over 20 to 30 minutes. Each dose > 500 mg/500 mg should be infused over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed.

4.3 **Contraindications**

- Hypersensitivity to the active substances or to any of the excipients listed in **section 6.1**
- Hypersensitivity to any other carbapenem antibacterial agent
- Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).

4.4 **Special warnings and precautions for use**

General

The selection of imipenem/cilastatin to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.

Hypersensitivity

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. Before initiating therapy with imipenem/cilastatin, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta-lactams and other allergens (see **section 4.3**). If an allergic reaction to imipenem/cilastatin occurs, discontinue the therapy immediately. **Serious anaphylactic reactions require immediate emergency treatment.**

Hepatic

Hepatic function should be closely monitored during treatment with imipenem/cilastatin due to the risk of hepatic toxicity (such as increase in transaminases, hepatic failure and fulminant hepatitis).

Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with imipenem/cilastatin. There is no dose adjustment necessary (see **section 4.2**).

Haematology

A positive direct or indirect Coombs test may develop during treatment with imipenem/cilastatin.

Antibacterial spectrum

The antibacterial spectrum of imipenem/cilastatin should be taken into account especially in life-threatening conditions before embarking on any empiric treatment. Furthermore, due to the limited susceptibility of specific pathogens associated with e.g. bacterial skin and soft-tissue infections, to

imipenem/cilastatin, caution should be exercised. The use of imipenem/cilastatin is not suitable for treatment of these types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment. Concomitant use of an appropriate anti-MRSA agent may be indicated when MRSA infections are suspected or proven to be involved in the approved indications. Concomitant use of an aminoglycoside may be indicated when *Pseudomonas aeruginosa* infections are suspected or proven to be involved in the approved indications (see **section 4.1**).

Interaction with valproic acid

The concomitant use of imipenem/cilastatin and valproic acid/sodium valproate is not recommended (see **section 4.5**).

Clostridioides difficile

Antibiotic-associated colitis and pseudomembranous colitis have been reported with imipenem/cilastatin and with nearly all other anti-bacterial agents and may range from mild to life-threatening in severity. It is important to consider this diagnosis in patients who develop diarrhoea during or after the use of imipenem/cilastatin (see **section 4.8**). Discontinuation of therapy with imipenem/cilastatin and the administration of specific treatment for *Clostridioides difficile* should be considered. Medicinal products that inhibit peristalsis should not be given.

Meningitis

Imipenem/cilastatin is not recommended for the therapy of meningitis.

Renal impairment

Imipenem-cilastatin accumulates in patients with reduced kidney function. CNS adverse reactions may occur if the dose is not adjusted to the renal function (see **sections 4.2** and **4.4** “Central nervous system” in this section).

Central nervous system

CNS adverse reactions such as myoclonic activity, confusional states, or seizures have been reported, especially when recommended doses based on renal function and body weight were exceeded. These experiences have been reported most commonly in patients with CNS disorders (e.g. brain lesions or history of seizures) and/or compromised renal function in whom accumulation of the administered entities could occur. Hence close adherence to recommended dose schedules is urged especially in these patients (see **section 4.2**). Anticonvulsant therapy should be continued in patients with a known seizure disorder.

Special awareness should be made to neurological symptoms or convulsions in children with known risk factors for seizures, or on concomitant treatment with medicinal products lowering the seizures threshold.

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically and placed on anticonvulsant therapy if not already instituted. If CNS symptoms continue, the dose of imipenem-cilastatin should be decreased or discontinued.

Patients with creatinine clearances of <15 ml/min should not receive imipenem-cilastatin unless haemodialysis is instituted within 48 hours. For patients on haemodialysis, imipenem-cilastatin is recommended only when the benefit outweighs the potential risk of seizures (see **section 4.2**).

Paediatric population

Reported clinical data are insufficient to recommend the use of imipenem-cilastatin in children under 1 year of age or paediatric patients with impaired renal function (serum creatinine >2 mg/dl). See also above under "Central nervous system".

4.5 Interaction with other medicinal products and other forms of interaction

Generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. These medicinal products should not be used concomitantly unless the potential benefit outweighs the risks.

Decreases in valproic acid levels that may fall below the therapeutic range have been reported when valproic acid was co-administered with carbapenem agents. The lowered valproic acid levels can lead to inadequate seizure control; therefore, concomitant use of imipenem and valproic acid/sodium valproate is not recommended and alternative antibacterial or anti-convulsant therapies should be considered (see **section 4.4**).

Oral anti-coagulants

Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects.

There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.

It has been reported that concomitant administration of imipenem-cilastatin and probenecid resulted in minimal increases in the plasma levels and plasma half-life of imipenem. The urinary recovery of active (non-metabolised) imipenem decreased to approximately 60% of the dose when imipenem-cilastatin was administered with probenecid. Concomitant administration of imipenem-cilastatin and probenecid doubled the plasma level and half-life of cilastatin, but had no effect on urine recovery of cilastatin.

Paediatric population

Interaction studies have only been reported in adults.

4.6 Fertility, Pregnancy and lactation

Pregnancy

There are no adequate and well-controlled studies reported for the use of imipenem/cilastatin in pregnant women.

The reported studies in pregnant monkeys have shown reproductive toxicity (see **section 5.3**). The potential risk for humans is unknown. Imipenem/cilastatin should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Breast-feeding

Imipenem and cilastatin are excreted into the mother's milk in small quantities. Little absorption of either compound occurs following oral administration. Therefore, it is unlikely that the suckling infant will be exposed to significant quantities. If the use of imipenem-cilastatin is deemed necessary, the benefit of breast feeding for the child should be weighed against the possible risk for the child.

Fertility

There are no reported data available regarding potential effects of imipenem/cilastatin treatment on male or female fertility.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been reported. However, there are some side effects (such as hallucination, dizziness, somnolence, and vertigo) associated with this product that may affect some patients' ability to drive or operate machinery (see **section 4.8**).

4.8 Undesirable effects

The most frequently systemic adverse reactions that were reported at least possibly related to therapy (imipenem/cilastatin given intravenously) were nausea, diarrhoea, vomiting, rash, fever, hypotension, seizures (see section 4.4), dizziness, pruritus, urticaria, somnolence. Similarly, the most frequently reported local adverse reactions were phlebitis/thrombophlebitis, pain at the injection site, erythema at the injection site and vein induration. Increases in serum transaminases and in alkaline phosphatase are also commonly reported.

The following adverse reactions have been reported in clinical studies or during post-marketing experience.

All adverse reactions are listed under system organ class and frequency: Very common ($\geq 1/10$), Common ($\geq 1/100$ to $< 1/10$), Uncommon ($\geq 1/1,000$ to $< 1/100$), Rare ($\geq 1/10,000$ to $< 1/1,000$), Very rare ($< 1/10,000$) and not known (cannot be estimated from the reported data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ Class	Frequency	Event
<i>Infections and infestations</i>	Rare	pseudomembranous colitis, candidiasis
	Very rare	gastro-enteritis
<i>Blood and lymphatic system disorders</i>	Common	eosinophilia
	Uncommon	pancytopenia, neutropenia, leucopenia, thrombocytopenia, thrombocytosis
	Rare	agranulocytosis
	Very rare	haemolytic anaemia, bone marrow depression
	Rare	anaphylactic reactions
<i>Immune system disorders</i>	Rare	anaphylactic reactions
<i>Psychiatric disorders</i>	Uncommon	psychic disturbances including hallucinations and confusional states
<i>Nervous system disorders</i>	Uncommon	seizures, myoclonic activity, dizziness, somnolence
	Rare	encephalopathy, paraesthesia, focal tremor, taste perversion
	Very rare	aggravation of myasthenia gravis, headache
	Not known	agitation, dyskinesia
<i>Ear and labyrinth disorders</i>	Rare	hearing loss
	Very rare	vertigo, tinnitus
<i>Cardiac disorders</i>	Very rare	cyanosis, tachycardia, palpitations
<i>Vascular disorders</i>	Common	thrombophlebitis
	Uncommon	hypotension
	Very rare	flushing
<i>Respiratory, thoracic and mediastinal disorders</i>	Very rare	dyspnoea, hyperventilation, pharyngeal pain
<i>Gastrointestinal disorders</i>	Common	diarrhoea, vomiting, nausea Medicinal product-related nausea and/or vomiting appear to occur more frequently in granulocytopenic patients than in non-granulocytopenic patients treated with imipenem/cilastatin
	Rare	staining of teeth and/or tongue
	Very rare	haemorrhagic colitis, abdominal pain, heartburn, glossitis, tongue papilla hypertrophy, increased salivation
<i>Hepatobiliary disorders</i>	Rare	hepatic failure, hepatitis
	Very rare	fulminant hepatitis
<i>Skin and subcutaneous tissue disorders</i>	Common	rash (e.g. exanthematous)
	Uncommon	urticaria, pruritus
	Rare	toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis
	Very rare	hyperhidrosis, skin texture changes
<i>Musculoskeletal and connective tissue disorders</i>	Very rare	polyarthralgia, thoracic spine pain
<i>Renal and urinary disorders</i>	Rare	acute renal failure, oliguria/anuria, polyuria, urine discoloration (harmless and should not be confused with haematuria) The role of imipenem-cilastatin in changes in renal function is difficult to assess, since factors predisposing to pre-renal azotemia or to impaired renal function usually have been present.
<i>Reproductive system and breast disorders</i>	Very rare	pruritus vulvae
<i>General disorders and administration site conditions</i>	Uncommon	fever, local pain and induration at the injection site, erythema at the injection site
	Very rare	chest discomfort, asthenia/weakness
<i>Investigations</i>	Common	increases in serum transaminases, increases in serum alkaline phosphatase
	Uncommon	A positive direct Coombs' test, prolonged prothrombin time, decreased haemoglobin, increases in serum bilirubin, elevations

Paediatric population (≥ 3 months of age)

In paediatric patients ≥ 3 months of age, the reported adverse reactions were consistent with those reported for adults.

4.9 Overdose

Symptoms of overdose that can occur are consistent with the adverse reaction profile; these may include seizures, confusion, tremors, nausea, vomiting, hypotension, bradycardia. No specific information is reported on treatment of overdose with imipenem-cilastatin. Imipenem-cilastatin sodium is haemodialyzable. However, usefulness of this procedure in the overdose setting is unknown.

5. PHARMACOLOGICAL PROPERTIES ¹

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use, carbapenems, ATC code: J01D H51

Mechanism of action

BACQUIRE consists of two components: imipenem and cilastatin sodium in a 1:1 ratio by weight.

Imipenem, also referred to as N-formimidoyl-thienamycin, is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium *Streptomyces cattleya*.

Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).

Cilastatin sodium is a competitive, reversible and specific inhibitor of dehydropeptidase-I, the renal enzyme which metabolizes and inactivates imipenem. It is devoid of intrinsic antibacterial activity and does not affect the antibacterial activity of imipenem.

Pharmacokinetic/Pharmacodynamic (PK/PD) relationship

Similar to other beta-lactam antibacterial agents, the time that imipenem concentrations exceed the MIC ($T > MIC$) has been reported to best correlate with efficacy.

Mechanism of resistance

Resistance to imipenem may be due to the following:

- Decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins)
- Reduced affinity of PBPs to imipenem

- Imipenem is stable to hydrolysis by most beta-lactamases, including penicillinases and cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of relatively rare carbapenem hydrolysing beta-lactamases. Species resistant to other carbapenems do generally express co-resistance to imipenem. There is no target-based cross-resistance between imipenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes.

Susceptibility

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Commonly susceptible species:
Gram-positive aerobes:
<i>Enterococcus faecalis</i>
<i>Staphylococcus aureus</i> (Methicillin-susceptible)*
<i>Staphylococcus</i> coagulase negative (Methicillin-susceptible)
<i>Streptococcus agalactiae</i>
<i>Streptococcus pneumoniae</i>
<i>Streptococcus pyogenes</i>
<i>Streptococcus viridans</i> group
Gram-negative aerobes:
<i>Citrobacter freundii</i>
<i>Enterobacter cloacae</i>
<i>Escherichia coli</i>
<i>Haemophilus influenzae</i>
<i>Klebsiella oxytoca</i>
<i>Klebsiella pneumoniae</i>
<i>Klebsiella aerogenes</i> (formerly <i>Enterobacter aerogenes</i>)
<i>Moraxella catarrhalis</i>
<i>Serratia marcescens</i>
Gram-positive anaerobes:
<i>Clostridium perfringens</i> **
<i>Peptostreptococcus</i> spp.**
Gram-negative anaerobes:
<i>Bacteroides fragilis</i>
<i>Bacteroides fragilis</i> group
<i>Fusobacterium</i> spp.
<i>Porphyromonas asaccharolytica</i>
<i>Prevotella</i> spp.
<i>Veillonella</i> spp.
Species for which acquired resistance may be a problem:
Gram-negative aerobes:
<i>Acinetobacter calcoaceticus baumannii</i> complex
<i>Pseudomonas aeruginosa</i>
Inherently resistant species:
Gram positive aerobes:
<i>Enterococcus faecium</i>
Gram negative aerobes:
Some strains of <i>Burkholderia cepacia</i> complex
<i>Legionella</i> spp.
<i>Stenotrophomonas maltophilia</i> (formerly <i>Xanthomonas maltophilia</i> , formerly <i>Pseudomonas maltophilia</i>)

Others:
<i>Chlamydia</i> spp.
<i>Chlamydophila</i> spp.
<i>Mycoplasma</i> spp.
<i>Ureoplasma urealyticum</i>

*All methicillin-resistant staphylococci are resistant to imipenem/cilastatin.

**EUCAST non-species related breakpoint is used.

5.2 Pharmacokinetics properties

Imipenem

Absorption

In normal volunteers, intravenous infusion of imipenem-cilastatin over 20 minutes resulted in peak plasma levels of imipenem ranging from 12 to 20 µg/ml for the 250 mg/250 mg dose, from 21 to 58 µg/ml for the 500 mg/500 mg dose, and from 41 to 83 µg/ml for the 1000 mg/1000 mg dose. The mean peak plasma levels of imipenem following the 250 mg/250 mg, 500 mg/500 mg, and 1000 mg /1000 mg doses were 17, 39, and 66 µg/ml, respectively. At these doses, plasma levels of imipenem decline to below 1 µg/ml or less in four to six hours.

Distribution

The binding of imipenem to human serum proteins has been reported to be approximately 20%.

Biotransformation

When administered alone, imipenem has been reported to be metabolised in the kidneys by dehydropeptidase-I. Individual urinary recoveries ranged from 5 to 40%, with an average recovery of 15-20% in several reported studies.

Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and has been reported to effectively inhibit metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.

Elimination

The plasma half-life of imipenem has been reported to be one hour. Approximately 70% of the administered antibiotic has been reported to be recovered intact in the urine within ten hours, and no further urinary excretion of imipenem was detectable. Urine concentrations of imipenem have been reported to exceed 10 µg/ml for up to eight hours after a 500 mg/500 mg dose of imipenem-cilastatin. The remainder of the administered dose has been reported to be recovered in the urine as antibacterially inactive metabolites, and faecal elimination of imipenem was essentially nil.

No accumulation of imipenem in plasma or urine has been reported with regimens of imipenem-cilastatin, administered as frequently as every six hours, in patients with normal renal function.

Cilastatin

Absorption

Peak plasma levels of cilastatin, following a 20-minute intravenous infusion of imipenem-cilastatin, has been reported to range from 21 to 26 µg/ml for the 250 mg/250 mg dose, from 21 to 55 µg/ml for

the 500 mg/500 mg dose and from 56 to 88 µg/ml for the 1000mg/1000 mg dose. The mean peak plasma levels of cilastatin following the 250 mg/250 mg, 500 mg/500 mg, and 1000mg/1000 mg doses have been reported to be 22, 42, and 72 µg/ml respectively.

Distribution

The binding of cilastatin to human serum proteins has been reported to be approximately 40%.

Biotransformation and elimination

The plasma half-life of cilastatin has been reported to be approximately one hour. Approximately 70-80% of the dose of cilastatin was recovered unchanged in the urine as cilastatin within 10 hours of administration of imipenem-cilastatin. No further cilastatin appeared in the urine thereafter. Approximately 10% was found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase comparable to that of cilastatin. Activity of dehydropeptidase-I in the kidney returned to normal levels shortly after the elimination of cilastatin from the blood stream.

Pharmacokinetics in special populations

Renal insufficiency

It has been reported that following a single 250 mg/250 mg intravenous dose of imipenem-cilastatin, the area under the curve (AUCs) for imipenem increased 1.1-fold, 1.9-fold, and 2.7-fold in subjects with mild (Creatinine Clearance (CrCL) 50-80 ml/min/1.73 m²), moderate (CrCL 30-<50 ml/min/1.73 m²), and severe (CrCL <30 ml/min/1.73 m²) renal impairment, respectively, compared to subjects with normal renal function (CrCL >80 ml/min/1.73 m²), and AUCs for cilastatin increased 1.6-fold, 2.0-fold, and 6.2-fold in subjects with mild, moderate, and severe renal impairment, respectively, compared to subjects with normal renal function. Following a single 250 mg/250 mg intravenous dose of imipenem-cilastatin given 24 hours after haemodialysis, AUCs for imipenem and cilastatin were reported to be 3.7-fold and 16.4-fold higher, respectively, as compared to subjects with normal renal function. Urinary recovery, renal clearance and plasma clearance of imipenem and cilastatin has been reported to decrease with decreasing renal function following intravenous administration of imipenem-cilastatin. Dose adjustment is necessary for patients with impaired renal function (see **section 4.2**).

Hepatic insufficiency

The pharmacokinetics of imipenem in patients with hepatic insufficiency have not been established. Due to the limited extent of hepatic metabolism of imipenem, its pharmacokinetics are not expected to be affected by hepatic impairment. Therefore, no dose adjustment is recommended in patients with hepatic impairment (see **section 4.2**).

Paediatric population

The average clearance (CL) and volume of distribution (V_{dss}) for imipenem have been reported to be approximately 45% higher in paediatric patients (3 months to 14 years) as compared to adults. The AUC for imipenem following administration of 15/15 mg/kg per body weight of imipenem/cilastatin to paediatric patients has been reported to be approximately 30% higher than the exposure in adults receiving a 500 mg/500 mg dose. At the higher dose, the exposure following administration of 25/25 mg/kg imipenem/cilastatin to children was reported 9% higher as compared to the exposure in adults receiving a 1000 mg/1000 mg dose.

Elderly

In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of imipenem-cilastatin 500 mg/500 mg administered intravenously over 20 minutes were reported to be consistent with those expected in subjects with slight renal impairment for which no dose alteration is considered necessary. The mean plasma half-lives of imipenem and cilastatin have been reported to be 91 ± 7.0 minutes and 69 ± 15 minutes, respectively. Multiple dosing has no effect on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of imipenem/cilastatin has been reported (see **section 4.2**).

5.3 Preclinical safety data

The reported non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity studies.

The reported animal studies showed that the toxicity produced by imipenem, as a single entity, was limited to the kidney. Co-administration of cilastatin with imipenem in a 1:1 ratio prevented the nephrotoxic effects of imipenem in rabbits and monkeys. The reported evidence suggests that cilastatin prevents the nephrotoxicity by preventing entry of imipenem into the tubular cells.

A reported teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin sodium at doses of 40/40 mg/kg/day (bolus intravenous injection) resulted in maternal toxicity including emesis, inappetence, body weight loss, diarrhoea, abortion, and death in some cases. When doses of imipenem-cilastatin sodium (approximately 100/100 mg/kg/day or approximately 3 times the usual recommended daily human intravenous dose) were administered to pregnant cynomolgus monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal maternal intolerance (occasional emesis), no maternal deaths, no evidence of teratogenicity, but an increase in embryonic loss relative to control groups (see **section 4.6**).

Long term studies in animals have not been reported to evaluate carcinogenic potential of imipenem-cilastatin.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium bicarbonate

6.2 Incompatibilities

Not applicable

6.3 Shelf Life

24 Months

6.4 Special Precautions for Storage

Store below 30°C, protect from light.

6.5 Nature and Contents of Container

1's Vial

6.6 Special precautions for disposal and other handling

Not applicable.

7. MARKETING AUTHORISATION HOLDER

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregoan (E)
Mumbai, Maharashtra

8. MARKETING AUTHORISATION NUMBER

04-9478

9. DATE OF FIRST AUTHORISATION

02-09-2003

10. DATE OF PREPARATION OF THE TEXT

December 2023

REFERENCES

1. Summary of Product Characteristics of Primaxin IV 500 mg/500 mg powder for solution for infusion, Merck Sharp & Dohme (UK) Limited, August 2023.

PRIMAXIN is the registered trademark of Merck Sharp & Dohme (UK) Ltd. and is not the trademark of Sun Pharmaceutical Industries Ltd. The maker of this brand is not affiliated with and does not endorse Sun Pharmaceutical Industries Ltd or its products.

Online coding shall be done during packaging with GTIN, batch details and serial no. in 2 D data matrix Barcode




GTIN
Lot
Mfd
Exp
S.N.

This Serial number will be unique for each pack



[5130924] - CT BACQUIRE INJ 500MG 1S
MARKET : NIGE
SIZE : 50X40X90MM
SPIL-DWS : 20.11.17US, 18.11.17US/US1,
11/11/2017VS, 09.11.17US,
06/11/2017VS/V1
REFERENCE CODE : 5117225
PHARMA CODE : 9108

Box Should Not Be Printed



Area For Sequential Number (OID)
e.g. OID: 00000000000000
& Scratch Lamination (HID)
XXXXXXXXXXXX 6 pt. (min.)